Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Go back to Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 53.99 +2.29 (4.43%)
Previous Close $51.70    52 Week High $35.13 
Open $52.10    52 Week Low $28.10 
Day High $54.00    P/E N/A 
Day Low $51.99    EPS $0.00 
Volume 2,182,019       

Brown & Brown, Inc. (NYSE: RO) Delayed: 8.49 +0.55 (6.93%)
Previous Close $7.94    52 Week High $8.59 
Open $7.94    52 Week Low $7.82 
Day High $8.59    P/E 6.53 
Day Low $7.82    EPS $1.30 
Volume 42,732       

Roper Industries (NASDAQ: ROP) Delayed: 360.15 +23.44 (6.96%)
Previous Close $336.71    52 Week High $195.93 
Open $365.74    52 Week Low $155.79 
Day High $369.15    P/E 67.07 
Day Low $355.02    EPS $5.37 
Volume 840,697